The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95

Blood

Volumn 105, Issue 3, 2005, Pages 948-958

  Woessmann, Wilhelm ^b   Seidemann, Kathrin ^b   Mann, Georg ^b   Zimmermann, Martin ^b   Burkhardt, Birgit ^b   Oschlies, Ilske ^b   Ludwig, Wolf Dieter ^b   Klingebiel, Thomas ^b   Graf, Norbert ^b   Gruhn, Bernd ^b   Juergens, Heribert ^b   Niggli, Felix ^b   Parwaresch, Reza ^b   Gadner, Helmut ^b   Riehm, Hansjoerg ^b   Schrappe, Martin ^b   Reiter, Alfred ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; IFOSFAMIDE; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISOLONE; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CONTROLLED STUDY; DIARRHEA; FEMALE; HIGH RISK POPULATION; HUMAN; INFECTION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE;

EID: 19944431916     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-03-0973     Document Type: Article

References (29)

1. Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol. 1996;14:1252-1261.
2. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925-934.
3. Brecher ML, Schwenn MR, Coppes MJ, et al. Fractionated cyclophosphamide and back to back high dose methotrexate and cytosine araginoside improves outcome in patients with stage III high grade small non-cleaved cell lymphomas (Snccl): a randomized trial of the Pediatric Oncology Group. Med Pediatr Oncol. 1997;29:526-533.
4. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM90. Blood. 1999;49:3294-3306.
5. Atra A, Imeson JD, Hobson R, et al. Improved outcome in children with advanced stage B-cell non Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer. 2000;82:1396-1402.
6. Patte C, Auperin A, Michon J, et al. The Societe Francasie d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97:3370-3379.
7. Cairo MS, Krailo MD, Morse M, et al. Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia. 2002;6:594-600.
8. Spreafico F, Massimino M, Luksch R, et al. Intensive, very short chemotherapy for advanced Burkitt's lymphoma in children. J Clin Oncol. 2002;20:2783-2788.
9. Reiter A, Schrappe M, Ludwig WD, et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood. 1992;80:2471-2478.
10. Warren RD, Nichols AP, Bender RA. Membrane transport of methotrexate in human lymphoblastoid cells. Cancer Res. 1978;38:668-671.
11. Chello PL, Sirotnak FM, Dorick DM. Alterations in kinetics of methotrexate transport during growth of L1210 murine leukemia cells in culture. Mol Pharmacol. 1980;18:274-278.
12. O'Keefe DA, Capizzi RL, Rudnick SA. Methotrexate cytotoxicity for L5178Y/ASN-lymphoblasts relationship of dose and duration of exposure to tumor cell viability. Cancer Res. 1982;42:1641-1647.
13. Kennedy DG, Van den Berg HW, Clarke R, et al. The effect of the rate of cell proliferation on the synthesis of methotrexate poly-gamma-glutamates in two human breast cancer cell lines. Biochem Pharmacol. 1985;34:3087-3093.
14. Wolfrom C, Hartmann R, Fengler R, et al. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia [see comments]. J Clin Oncol. 1993;11:827-833.
15. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas [erratum appears in Lancet. 1998;13:372]. Lancet. 1988;1:292-293.
16. World Health Organization Classification of Tumours. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology & Genetics: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
17. Murphy SB. Classification, staging and end results of treatment in childhood non-Hodgkin's lymphoma: dissimilarities from lymphomas in adults. Sem Oncol. 1980;7:332-339.
18. Sakiroglu C, Patte C, Michon J, et al. Use of uricozyme® and occurrence of metabolic problems during initial phase of the LMB 89 protocol [abstract]. Med Ped Oncol. 1997;29:331.
19. Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997;11:1813-1816.
20. Wössmann W, Schrappe M, Meye U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol. 2003;82:160-165.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
23. Greenwood M. A report on the natural duration of cancer. In: Reports on Public Health and Statistical Subjects, Vol 33, appendix 1. London, United Kingdom: Her Majesty's Stationery Office; 1926:1-26.
24. Cox DR. Regression models and lile tables. J R Stat Soc. 1972;34:187-220.
25. ICH Expert Working Group & International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Statistical Principles for Clinical Trials E9. http://www.ich.org/MediaServer.jser?@_ID=485&@_MODE=GLB. 1998.
26. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
27. Seidemann K, Tiemann M, Lauterbach I, et al. Primary medistinal (thymic) large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt- Münster (BFM) group. J Clin Oncol. 2003;21:1782-1789.
28. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 1984;44:3643-3653.
29. Gentet JC, Patte C, Quintana E, et al. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkins lymphoma: a study of the French Society of Pediatric Oncology. J Clin Oncol. 1990;8:661-665.